In addition, we showed that the combination of these PHB ligands with the BRAF inhibitor Dabrafenib overcame innate resistance in a BRAF mutant melanoma line (MM029), while it was less pronounced in a BRAFi-sensitive line (MM074) (Figure 8A). The gene discussed is BRAF; the disease is melanoma.